Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
Paul Moayyedi, John W. Eikelboom, Jackie Bosch, et al.
Gastroenterology (2019) Vol. 157, Iss. 3, pp. 682-691.e2
Open Access | Times Cited: 399

Showing 51-75 of 399 citing articles:

Proton pump inhibitors: Understanding the associated risks and benefits of long-term use
Kristina M. Thurber, Ashley O Otto, Shawna L Stricker
American Journal of Health-System Pharmacy (2023) Vol. 80, Iss. 8, pp. 487-494
Closed Access | Times Cited: 20
The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance
M. Alexandra Lake, Kristin N. Adams, Feilin Nie, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 7
Open Access | Times Cited: 18
Individualized prevention of proton pump inhibitor related adverse events by risk stratification
Bin Xia, Qiangsheng He, Fang Gao Smith, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 7
Peptic Ulcer Disease
Nimish Vakil
JAMA (2024)
Closed Access | Times Cited: 7
Long-Term Proton Pump Inhibitor Use: Review of Indications and Special Considerations
Amrit K. Kamboj, Dhyanesh A. Patel, Rena Yadlapati
Clinical Gastroenterology and Hepatology (2024) Vol. 22, Iss. 7, pp. 1373-1376
Closed Access | Times Cited: 6
Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study
Naomi Uemura, Yoshikazu Kinoshita, Ken Haruma, et al.
Clinical Gastroenterology and Hepatology (2024)
Open Access | Times Cited: 6
Aspirin versus Clopidogrel Monotherapy After Percutaneous Coronary Intervention: 1-Year Follow-up of the STOPDAPT-3 Trial
Hirotoshi Watanabe, Masahiro Natsuaki, Takeshi Morimoto, et al.
European Heart Journal (2024)
Open Access | Times Cited: 6
Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future
László Herszényi, Tamás Bakucz, Lóránd Barabás, et al.
Digestive Diseases (2019) Vol. 38, Iss. 2, pp. 104-111
Open Access | Times Cited: 50
The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing
T. S. Dharmarajan
Journal of the American Medical Directors Association (2020) Vol. 22, Iss. 1, pp. 15-22
Closed Access | Times Cited: 48
Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO)
Maurizio Giuseppe Abrignani, Luigi Gatta, Domenico Gabrielli, et al.
European Journal of Internal Medicine (2020) Vol. 85, pp. 1-13
Open Access | Times Cited: 47
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective
Bianca Rocca, Carlo Patrono
Diabetes Research and Clinical Practice (2020) Vol. 160, pp. 108008-108008
Closed Access | Times Cited: 46
Potential proton pump inhibitor–related adverse effects
Issac E. Perry, Irene Sonu, Carmelo Scarpignato, et al.
Annals of the New York Academy of Sciences (2020) Vol. 1481, Iss. 1, pp. 43-58
Closed Access | Times Cited: 42
Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study
Devin Abrahami, Emily G. McDonald, Mireille E. Schnitzer, et al.
BMJ Open (2020) Vol. 10, Iss. 12, pp. e041529-e041529
Open Access | Times Cited: 42
Proton-Pump Inhibitor Use and the Risk of Community-Associated Clostridium difficile Infection
Malin Inghammar, Henrik Svanström, Marianne Voldstedlund, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 12, pp. e1084-e1089
Open Access | Times Cited: 42
Proton Pump Inhibitors
Felice Schnoll‐Sussman, Rachel Niec, Philip O. Katz
Gastrointestinal Endoscopy Clinics of North America (2020) Vol. 30, Iss. 2, pp. 239-251
Closed Access | Times Cited: 41
Optimal management of severe symptomatic gastroesophageal reflux disease
Nicholas J. Talley, Mudar Zand Irani
Journal of Internal Medicine (2020) Vol. 289, Iss. 2, pp. 162-178
Open Access | Times Cited: 40
Physicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey
Jacob E. Kurlander, Joel H. Rubenstein, Caroline R. Richardson, et al.
The American Journal of Gastroenterology (2020) Vol. 115, Iss. 5, pp. 689-696
Open Access | Times Cited: 39
Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis
Leander Muheim, Andri Signorell, Stefan Markun, et al.
Therapeutic Advances in Gastroenterology (2021) Vol. 14
Open Access | Times Cited: 38
Association of proton‐pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta‐analyses of cohort studies and randomised controlled trials
Sajesh K. Veettil, Saranrat Sadoyu, Elizabeth Bald, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 4, pp. 1551-1566
Open Access | Times Cited: 38
Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system
Bin Wu, Dan Li, Ting Xu, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 37
Small Intestinal Bacterial Overgrowth
Daniel Bushyhead, Eamonn M.M. Quigley
Gastroenterology Clinics of North America (2021) Vol. 50, Iss. 2, pp. 463-474
Closed Access | Times Cited: 36
Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
Kadir Eser, Arif Hakan Önder, Emel Sezer, et al.
BMC Cancer (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 23
The Effects of Pantoprazole on Kidney Outcomes
Lonnie Pyne, Andrew Smyth, Amber O. Molnar, et al.
Journal of the American Society of Nephrology (2024)
Closed Access | Times Cited: 5
Association and Mechanisms of Proton Pump Inhibitors Use with Type-2 Diabetes Mellitus Incidence in Adults: A Systemic Review and Meta-Analysis
Santenna Chenchula, Phulen Sharma, Mohan Krishna Ghanta, et al.
Current Diabetes Reviews (2024) Vol. 20, Iss. 10
Closed Access | Times Cited: 4
Long-Term Use of Proton-Pump Inhibitors: Unravelling the Safety Puzzle
Manish S Bhatnagar, Sachin Choudhari, Dattatray Pawar, et al.
Cureus (2024)
Open Access | Times Cited: 4

Scroll to top